Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) announced recently that Anna Diaz Triola is appointed as the company’s Chief Commercial Officer. He assumed responsibilities with effect from July 19, 2021. The clinical-stage biopharmaceutical company develops and discovers antibacterial products. In his new position, Anna Diaz Triola will be responsible for commercial strategy, driving it for marketing and sales operations for the U.SUS.
Gearing up for product commercialization
The company is in the final stage of the clinical trial for ATTACK Phase 3. It is now moving towards the next stage of commercialization for its new product. The company said that it is ahead of the results from sulbactam-durlobactam. Anna Diaz Triola will be responsible for leadership and commercial enhancements for the company while also offering insights through her skills in diverse therapeutic areas like antibacterials. The company is now preparing for the commercialization of the R&D platform. With Anna’s commercialization capabilities, the company will enhance its R&D platform for becoming an anti-infective company.
About Anna Diaz Triola
Ms. Triola has more than 20 years of commercialization and launch experience in products across different therapeutic areas. She also has diverse settings across multiple areas like community and hospitals. Anna Diaz Triola has earlier served as the Marketing Vice President for Summit Therapeutics. She has played an instrumental role in developing a commercial strategy for the previous company against C. difficile infections. Additionally, she has also held key leadership roles in Biogen, Flexion Therapeutics, Cubist, and Chiasma.
Through her role, Ms. Anna will lead Entasis’ global commercial strategy that kicks off with its essential products, zoliflodacin, and SUL-DUR. Both the products address “urgent” bacterial threats, as defined by CDC. Ms. Anna said that the two products have the potential for impacting patients around the world significantly.
At present, the company is putting its efforts into tackling the antimicrobial resistance challenge.
